| 1.76 -0.02 (-1.12%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.9  |
1-year : | 3.48 |
| Resists | First : | 2.49 |
Second : | 2.98 |
| Pivot price | 2.09 |
|||
| Supports | First : | 1.7 |
Second : | 1.41 |
| MAs | MA(5) : | 1.87 |
MA(20) : | 2.23 |
| MA(100) : | 11.16 |
MA(250) : | 17 |
|
| MACD | MACD : | -1.3  |
Signal : | -1.6 |
| %K %D | K(14,3) : | 3.2 |
D(3) : | 5.5 |
| RSI | RSI(14): 19.5 |
|||
| 52-week | High : | 30.5 | Low : | 1.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMLX ] has closed above bottom band by 20.4%. Bollinger Bands are 80.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.84 - 1.86 | 1.86 - 1.87 |
| Low: | 1.67 - 1.68 | 1.68 - 1.7 |
| Close: | 1.74 - 1.76 | 1.76 - 1.78 |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop - Simply Wall St
Tue, 23 Apr 2024
Party Time: Brokers Just Made Major Increases To Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Earnings ... - Yahoo Canada Shine On
Fri, 05 Apr 2024
AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Thu, 04 Apr 2024
Amylyx Pharmaceuticals Enacts Major Restructuring and Refocuses Strategy - TipRanks.com - TipRanks
Thu, 04 Apr 2024
Amylyx to Pull ALS Drug From Market After Failed Trial - Bloomberg
Wed, 03 Apr 2024
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 68 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 105 (%) |
| Shares Short | 6,010 (K) |
| Shares Short P.Month | 4,370 (K) |
| EPS | 0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.51 |
| Profit Margin | 12.9 % |
| Operating Margin | 1.7 % |
| Return on Assets (ttm) | 5.3 % |
| Return on Equity (ttm) | 12.7 % |
| Qtrly Rev. Growth | 395.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.61 |
| EBITDA (p.s.) | 0.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 12 (M) |
| Levered Free Cash Flow | 38 (M) |
| PE Ratio | 2.51 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.26 |
| Price to Sales | 0.31 |
| Price to Cash Flow | 10 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|